Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 03:02PM ET
0.6752
Dollar change
+0.0581
Percentage change
9.42
%
Index- P/E- EPS (ttm)-2.98 Insider Own4.65% Shs Outstand7.71M Perf Week15.76%
Market Cap5.19M Forward P/E- EPS next Y-0.28 Insider Trans0.00% Shs Float7.33M Perf Month-0.71%
Income-13.04M PEG- EPS next Q0.28 Inst Own57.26% Short Float1.18% Perf Quarter20.55%
Sales0.00M P/S- EPS this Y99.88% Inst Trans0.72% Short Ratio0.05 Perf Half Y22.76%
Book/sh0.79 P/B0.85 EPS next Y-8300.84% ROA-77.27% Short Interest0.09M Perf Year-80.93%
Cash/sh0.32 P/C2.12 EPS next 5Y- ROE-142.88% 52W Range0.46 - 5.25 Perf YTD29.25%
Dividend Est.- P/FCF- EPS past 5Y56.98% ROI-211.44% 52W High-87.14% Beta-0.28
Dividend TTM- Quick Ratio2.90 Sales past 5Y-27.40% Gross Margin- 52W Low46.08% ATR (14)0.05
Dividend Ex-Date- Current Ratio2.90 EPS Y/Y TTM88.41% Oper. Margin0.00% RSI (14)57.46 Volatility6.60% 7.37%
Employees12 Debt/Eq0.02 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price3.67
Option/ShortNo / Yes LT Debt/Eq0.01 EPS Q/Q78.83% Payout- Rel Volume0.28 Prev Close0.62
Sales Surprise- EPS Surprise27.36% Sales Q/Q- EarningsMar 25 BMO Avg Volume1.63M Price0.68
SMA206.95% SMA506.47% SMA20013.18% Trades Volume395,560 Change9.42%
Today 06:45AM
Mar-25-24 07:00AM
Mar-08-24 07:00AM
Feb-01-24 08:14AM
Jan-31-24 06:40PM
05:15PM Loading…
05:15PM
Nov-17-23 01:54PM
Nov-09-23 07:18AM
Nov-04-23 12:15PM
Oct-16-23 07:00AM
Oct-03-23 07:00AM
Sep-21-23 07:00AM
Sep-18-23 07:00AM
Sep-14-23 07:01AM
Sep-01-23 07:00AM
01:43PM Loading…
Aug-29-23 01:43PM
Aug-23-23 07:33PM
07:00AM
Aug-22-23 01:06PM
Aug-16-23 07:00AM
Aug-08-23 07:00AM
Aug-03-23 07:00AM
Aug-01-23 07:00AM
Jul-05-23 07:00AM
Jun-23-23 08:35AM
Jun-20-23 10:58AM
Jun-15-23 07:00AM
Jun-14-23 08:00AM
Jun-06-23 04:30PM
Jun-02-23 08:30AM
07:00AM Loading…
May-09-23 07:00AM
May-01-23 07:00AM
Apr-27-23 02:55PM
Apr-26-23 07:00AM
Apr-21-23 07:00AM
Apr-17-23 07:00AM
Mar-30-23 07:00AM
Mar-23-23 07:00AM
Mar-10-23 07:00AM
Feb-09-23 12:00PM
Feb-07-23 08:00AM
07:00AM
Feb-03-23 07:00AM
Jan-09-23 07:00AM
Jan-03-23 07:01AM
Dec-14-22 08:19AM
Nov-18-22 08:30AM
Nov-17-22 06:45AM
Nov-09-22 06:45AM
Oct-31-22 08:01AM
Oct-17-22 08:00AM
Oct-13-22 06:45AM
Sep-28-22 11:44AM
Sep-26-22 06:45AM
Sep-13-22 06:45AM
Aug-15-22 06:30AM
Aug-12-22 06:45AM
Jul-28-22 06:45AM
Jul-26-22 04:38PM
Jul-22-22 08:30AM
Jul-05-22 06:45AM
Jun-27-22 06:53AM
May-31-22 04:30PM
Apr-25-22 06:45AM
Apr-15-22 09:00AM
Mar-21-22 06:45AM
Mar-18-22 12:00PM
06:45AM
Feb-08-22 06:45AM
Feb-01-22 06:45AM
Jan-05-22 07:00AM
Dec-15-21 07:00AM
Dec-14-21 07:15AM
Nov-15-21 07:30AM
Kiora Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes KIO-301, which is designed to restore vision in patients with inherited and age-related degenerative retinal disease, KIO-101 for patients with Ocular Presentation of Rheumatoid Arthritis, KIO-201 for patients undergoing PRK surgery for corneal wound repair after refractive surgery, and KIO-102. The company was founded in 1998 and is headquartered in Encinitas, CA.